Erin E. Jones serves as senior vice president and global head of regulatory affairs and quality assurance. Prior to Gritstone, he served as global head of regulatory, medical writing and pharmacology/toxicology at Puma Biotechnology, where he supported the late-stage development of neratinib. Earlier in his career, he worked at Genentech, where he held a variety of positions including head of regulatory intelligence and leader of the HER Franchise Regulatory Group, where he oversaw late-stage development, BLA submissions and ODAC preparations for Kadcyla™ and Perjeta™ in HER2-positive metastatic breast cancer, and led approvals for Herceptin™ in HER2-positive adjuvant breast and gastric cancers. Jones has directed the regulatory development of dozens of small molecules, monoclonal antibodies, antibody-drug conjugates, plasmids, adenoviral gene therapies, and companion diagnostics in oncology and hematology at BioMarin, Cephalon and Centocor. He received his M.S. in computer systems at Pennsylvania State University.